2026: a pivotal year for IsoMedica
With the commissioning of the Advanced Radioisotope Manufacturing Facility, securing Ra-228 feedstock and progressing Th-228 and Pb-212 production, entX is advancing its medical isotope platform towards commercial supply.

OTher Projects
2026 represents an important transition year for entX's IsoMedica medical isotope platform, as the company progresses from facility development towards production and commercial supply.
With the commissioning of the Advanced Radioisotope Manufacturing Facility (ARMF), entX is bringing its integrated isotope processing and purification capabilities online, while finalising Stage 1 production and qualifying key equipment.
Advancing Production and Securing Supply
A key milestone has been securing a dependable radium-228 (Ra-228) feedstock pathway, supporting the production of market-ready thorium-228 (Th-228) and progress towards commercial revenue.
This provides an important foundation for IsoMedica's production capability and the development of a reliable medical isotope supply chain.
Expanding Lead-212 Supply Opportunities
Looking ahead, entX is expanding its capability to supply lead-212 (Pb-212) for pre-clinical drug development, supporting Contract Research Organisations (CROs) and pharmaceutical partners as their radiopharmaceutical programs progress towards clinical trials.
Through the ARMF and its integrated production platform, IsoMedica is working to establish the infrastructure and supply capability needed to support the growing demand for medical isotopes and targeted alpha therapy.
2026 marks an important step in advancing entX's medical isotope operations towards commercial delivery.
